Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Alpha Tau Medical Ltd. Ordinary Shares · DRTS

DRTSNASDAQCommon stockCurrentCIK 1871321Updated Nov 20, 2026

Company: Alpha Tau Medical Ltd. →

DRTS price & chart

Provider market data

Loading TradingView…

NASDAQ:DRTS on TradingView ↗

TradingView · Data may be delayed

About the company

Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

6-K · 2026-11-19 · 0001213900-26-122234

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income-42,627,000USD · FY 2025
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

Operating income-42,288,000USD · FY 2025
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

Diluted EPS-0.53USD per share · FY 2025
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022FY 2025FY 2024FY 2023FY 2022
ASSETS
AssetsUSD110,954,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

96,048,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

111,206,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—105,652,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

86,204,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

107,388,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

120,149,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Property, Plant and Equipment, NetUSD17,285,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

12,354,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

7,549,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—19,661,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

13,934,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

12,798,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

7,471,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD11,703,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

2,763,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

855,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2023-06-30

—12,202,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

13,724,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

12,657,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

5,836,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Assets, CurrentUSD85,778,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

75,248,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

96,059,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—78,298,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

64,229,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

85,756,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

106,477,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Prepaid Expense and Other Assets, CurrentUSD2,525,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

1,102,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

1,698,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—1,395,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

1,374,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

816,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

1,097,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Operating Lease, Right-of-Use AssetUSD7,428,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

8,009,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

7,157,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—7,214,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

7,609,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

8,363,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

5,810,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD24,331,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

22,031,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

18,643,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—28,553,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

23,538,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

22,913,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

14,492,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Stockholders’ equity:
Additional Paid in CapitalUSD——196,045,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

———200,234,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

192,259,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Retained Earnings (Accumulated Deficit)USD-166,314,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

-131,109,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

-103,482,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—-190,136,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

-147,509,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

-115,759,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

-86,602,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Stockholders' Equity Attributable to ParentUSD86,623,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

74,017,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2024-06-30

92,563,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2023-06-30

108,268,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2022-06-30

77,099,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

62,666,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

84,475,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

105,657,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Additional Paid in Capital, Common StockUSD252,937,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

205,126,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

——267,235,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

210,175,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

——
Liabilities and EquityUSD110,954,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

96,048,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

111,206,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—105,652,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

86,204,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

107,388,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

120,149,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Current liabilities:
Liabilities, CurrentUSD8,156,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

6,456,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

5,416,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—10,507,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

8,675,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

7,102,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

4,338,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Operating Lease, Liability, CurrentUSD1,080,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

1,038,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

846,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—1,131,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

1,011,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

1,062,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

669,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Accounts Payable, CurrentUSD——1,789,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

———2,566,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

1,423,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Operating Lease, Liability, NoncurrentUSD6,201,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

6,109,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

5,433,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—6,243,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

5,964,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

6,604,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

4,524,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD————3,784,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

2,615,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

2,236,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

1,276,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Cash, Cash Equivalents, and Short-term InvestmentsUSD83,253,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

74,146,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

——76,903,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

62,855,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

84,940,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

—
Deferred Tax Liabilities, NetUSD————1,025,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

———
Short-term InvestmentsUSD67,996,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

68,268,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

92,672,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—60,924,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

45,876,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

69,131,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

98,694,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Other Assets, Noncurrent———
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2023-06-30

—————

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD————10,617,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

9,916,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

7,926,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

6,748,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Deferred Income Tax Expense (Benefit)USD————97,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

———
Net Cash Provided by (Used in) Operating ActivitiesUSD————-26,681,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-19,783,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-17,958,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-23,879,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD————-20,588,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

20,768,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

18,682,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-89,936,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Payments to Acquire Property, Plant, and EquipmentUSD————6,075,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

2,238,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

6,401,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

904,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD————45,768,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

25,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

5,297,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

96,905,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD————-1,522,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

1,067,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

5,971,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-17,168,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD11,703,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

2,763,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2024-06-30

1,689,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2023-06-30

12,363,000
Source

6-K · 2023-08-28 · 0001213900-23-071230

As of 2022-06-30

12,202,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

13,724,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

12,657,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

6,686,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

As of 2022-12-31

Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD————381,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

321,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

52,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

237,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD————-21,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

57,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-50,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-258,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD————10,617,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

9,916,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

7,926,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

6,748,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, and Short-term InvestmentsUSD83,253,000
Source

6-K · 2025-08-11 · 0001213900-25-074290

As of 2025-06-30

74,146,000
Source

6-K · 2024-08-14 · 0001213900-24-068971

As of 2024-06-30

——76,903,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

As of 2025-12-31

62,855,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

As of 2024-12-31

84,940,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

As of 2023-12-31

—
DepreciationUSD————1,232,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

1,102,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

1,074,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

979,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD—————106,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

—413,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Gain (Loss) on Disposition of Property Plant EquipmentUSD————-35,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

———
General and Administrative ExpenseUSD————8,363,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

6,673,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

7,332,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

10,272,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD———————-33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD———————33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD————121,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

6,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

16,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

20,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

InterestExpenseNonoperatingUSD————347,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

303,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

——
Net Income (Loss) Attributable to ParentUSD————-42,627,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-31,750,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-29,157,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Nonoperating Income (Expense)USD————-218,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

4,298,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

6,539,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

—
Proceeds from Issuance of Common StockUSD————45,496,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

———
Proceeds from Stock Options ExercisedUSD————272,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

25,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

49,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

27,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Operating Income (Loss)USD-42,288,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-36,042,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-35,680,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-32,136,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD-42,506,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-31,744,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-29,141,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-33,742,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD121,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

6,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

16,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

20,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD-42,627,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-31,750,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-29,157,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Earnings Per Share, BasicUSD per share-0.53
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-0.45
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-0.42
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-0.53
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Earnings Per Share, DilutedUSD per share-0.53
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-0.45
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

-0.42
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

-0.53
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Basicshares80,581,440
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

69,927,566
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

69,377,922
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

63,534,875
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares80,581,440
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

69,927,566
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

69,377,922
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

63,534,875
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Interest Expense (non-operating)USD347,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

303,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

——
Additional Financial Items
Current Income Tax Expense (Benefit)USD24,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

—16,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

20,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD—106,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

—413,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

General and Administrative ExpenseUSD8,363,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

6,673,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

7,332,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

10,272,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD———-33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD-42,331,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

-31,065,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

28,224,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

33,100,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD———33,762,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Per Basic ShareUSD per share———-0.53
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share———-0.53
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Nonoperating Income (Expense)USD-218,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

4,298,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

6,539,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

—
Other ExpensesUSD———16,547
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Research and Development ExpenseUSD32,065,000
Source

20-F · 2026-03-09 · 0001213900-26-025174

2025-01-01 to 2025-12-31

27,020,000
Source

20-F · 2025-03-12 · 0001213900-25-023187

2024-01-01 to 2024-12-31

26,424,000
Source

20-F · 2024-03-07 · 0001213900-24-020767

2023-01-01 to 2023-12-31

20,890,000
Source

20-F · 2023-03-09 · 0001213900-23-018883

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-295359

F-3 · 2026-04-28 · 0001213900-26-048160

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ea031235801ex99-1.htm · 6-K · 2026-11-19

Exhibit 99.1 Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update - New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% objective response rate, including five complete responses, in the first six evaluable patients at 6.9 months median follow-up, with 100% feasibility and no unanticipated serious adverse events - …

6-K · 2026-11-19 · 0001213900-26-122234

Read attachment ↗
ea031237801ex99-1.htm · 6-K · 2026-11-16

Exhibit 99.1 N A S D A Q / T A S E · D R T S R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1, 2 0 2 6 Alpha DaRT in the brain. Interim results as of November 11, 2026 from REGAIN, the U.S. trial of Alpha DaRT in recurrent glioblastoma, as presented at the SNO 2026 Annual Meeting. 8 of 8 patients alive · 100% feasibility · 6 of 6 objective responses in assessed patients 1 D I S C L A I M E R Important notices. This presentation (together with oral statements made in connection herew…

6-K · 2026-11-16 · 0001213900-26-120250

Read attachment ↗
ea031236301ex99-1.htm · 6-K · 2026-11-16

Exhibit 99.1 Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16 - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has …

6-K · 2026-11-16 · 0001213900-26-120072

Read attachment ↗
ea031155201ex99-1.htm · 6-K · 2026-11-12

Exhibit 99.1 Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial - Call to Follow Presentation of New Data at Upcoming Society for Neuro- Oncology SNO Conference - JERUSALEM, Nov. 12, 2026 -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that it will host a conference call and webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET t…

6-K · 2026-11-12 · 0001213900-26-118478

Read attachment ↗
ea031012301ex99-1.htm · 6-K · 2026-10-29

Exhibit 99.1 Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq and TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced tha…

6-K · 2026-10-29 · 0001213900-26-113681

Read attachment ↗
ea030933001ex99-1.htm · 6-K · 2026-10-22

Exhibit 99.1 Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT ® for Pancreatic Cancer Patients in Korea - MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancer…

6-K · 2026-10-22 · 0001213900-26-111493

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.